Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | FAAH | O00519 | 5/20 | 0.46 |
| ▸ | CES1 | P23141 | 5/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11821915 | 1.00 | CA2 (0.52) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL4081467 | 1.00 | CA2 (0.52) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL3239067 | 1.00 | CA2 (0.52) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL4073173 | 0.98 | CA2 (0.48) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL4073621 | 0.91 | CA2 (0.40) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL4006475 | 0.81 | — | — | |
| SCHEMBL28140282 | 0.81 | CA2 (0.50) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL28141077 | 0.81 | CA2 (0.50) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL28140302 | 0.81 | CA2 (0.50) | CA2FAAHCES1CES2TSHR | |
| Propane SCHEMBL8719519 | 0.79 | NLRP3 (0.37) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128662-A1 | Novel compounds for treatment of obesity | GPR119, FABP4, HSD17B4 | CA2 4544/4885FAAH 666/4885CES1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.